PsychiatricTimes Members: Login | Register

|     

PsychiatricTimes SearchMedica Medline Drugs

Powered by SearchMedica

 
Risk Assessment
News
Current Issues
Blogs
Special Reports
CME
Conferences
Resources
Careers
Multimedia
About Us
 

Home » Attention-Deficit/Hyperactivity Disorder

Psychiatric Times. Vol. 27 No. 7
INTEGRATIVE MEDICINE 

Integrative Management of ADHD: What the Evidence Suggests

By James Lake, MD | July 7, 2010
Dr Lake is in private practice in Monterey, Calif, and is on the clinical faculty in the department of psychiatry and behavioral sciences at Stanford University Hospital. He chairs the American Psychiatric Association Caucus on Complementary, Alternative, and Integrative Medicine (www.APACAM.org) and is the author of the Textbook of Integrative Mental Health Care (New York: Thieme Medical Publishers, Inc.; 2007) and Integrative Mental Health: A Therapist’s Handbook (New York: WW Norton and Company; 2009).

It is important for mental health professionals to be familiar with emerging research findings about widely used complementary and alternative medicine (CAM) treatments of ADHD in order to provide patients with accurate information on efficacy, safety, and appropriate use.

A high percentage of children and adults who have been given a diagnosis of ADHD use alternative therapies alone or in combination with conventional pharmacological treatment.1 More than half of parents of children with ADHD treat their children’s symptoms using 1 or more CAM therapies, most commonly vitamins, dietary changes, and expressive therapies; yet only about 10% disclose use of such nonpharmacological therapies to their child’s pediatrician.2 Most nonpharmacological therapies used to treat ADHD are supported by limited evidence; however, as many as 80% of patients who use herbal preparations and other natural products regard these therapies as the primary treatment of their symptoms.2

(MORE: Alternative Medicine Therapies for ADHD)

Conventional treatment

Stimulant medications, including dextroamphetamine, methylphenidate(Drug information on methylphenidate), and related compounds, are the most widely used treatments of ADHD. The nonstimulant atomoxetine(Drug information on atomoxetine) has less potential for abuse but also may be less effective than stimulants.3 SSRIs and other antidepressants are used with varying degrees of success. Behavioral modification aimed at rewarding desirable behavior and extinguishing disruptive or inappropriate behavior continues to be a mainstay of conventional treatment. Psychotherapy and psychosocial support help reduce anxiety and feelings of loss of control that frequently accompany ADHD. It is estimated that ADHD is correctly diagnosed and treated in fewer than one-fifth of adults, which results in significant social and occupational morbidity.

Limitations and risks of conventional treatment

Long-term amphetamine use in childhood is associated with delays in normal development.4 One-third of individuals of all ages who take stimulants for ADHD report significant adverse effects, including insomnia, decreased appetite, and abdominal pain.5 Cases of stimulant-induced psychosis have also been reported.6 Stimulants and other conventional treatments of ADHD in adults are probably only half as effective as they are in children.4

Adverse effects of nonstimulant drugs used to treat ADHD include hypertension, decreased appetite, nausea, fatigue, liver toxicity, insomnia, and seizures. A meta-analysis of 6 controlled trials concluded that stimulant therapy started in childhood reduces the risk of subsequent substance abuse by as much as one-half. In contrast, stimulants started in adolescence or adulthood increase the risk of future substance abuse.7 Nonstimulant medications and extended-release stimulants are less likely to be abused.8

As many as 80% of patients who use herbal preparations and other natural products regard these therapies as the primary treatment of their [ADHD] symptoms.

Nonconventional therapies

Dietary changes. Early studies on a highly restrictive diet that eliminates all processed foods reported promising findings in children with ADHD9; however, a review of controlled studies failed to support these findings.10 The oligoantigenic diet (OAD) is a highly restrictive elimination diet in which food colorings and additives as well as dairy products, sugar, wheat, corn, citrus, eggs, soy, yeast, nuts, and chocolate are eliminated. Numerous studies on the OAD reported significant reductions in hyperactivity in children with ADHD when specific food items were eliminated from the diet using an open-label protocol.11 In most studies, symptoms recurred when children were subsequently challenged with the eliminated food item following a placebo-controlled protocol. The significance of findings on elimination diets is limited by study design flaws, including heterogeneity of patient populations, absence of standardized outcome measures, high dropout rates and, in some studies, nonblinded raters.

Although research findings are mixed, sugar has long been suspected as an underlying causative factor in ADHD. In a 9-week placebo-controlled study, children without ADHD who were randomized to diets high in sucrose, aspartame, or saccharin showed no differences in behavior.12 The expectations of parents may bias the perceptions of their children’s behavior following the consumption of large quantities of sugar. In one controlled trial, mothers who believed their child had eaten sugar were more likely to label their child’s behavior as hyperactive.13

In their comprehensive review of nonpharmacological therapies for ADHD, Weber and Newmark14 remarked that the study design did not adequately control for fruits, juices, or other dietary sources of sugar and suggested that future studies should not focus primarily on sugar but rather on a possible link between high-glycemic-index foods and hyperactivity. Large prospective controlled studies on dietary restrictions as therapeutic interventions in ADHD have been elusive because of difficulties in controlling eating behavior in both children and adults.15

EEG biofeedback. Children and adults with ADHD often have abnormal patterns of brain electrical activity; underarousal in frontal and midline cortical regions is found in up to 90% of cases, and frontal hyperarousal is especially noted in individuals who have not responded to stimulants.16 Electroencephalographic (EEG) biofeedback is aimed at normalizing EEG activity by correcting the brain’s state of relative underarousal, thereby optimizing cognitive and behavioral functioning.17

Two EEG biofeedback protocols have been extensively studied as treatments of ADHD. With sensorimotor rhythm (SMR) training, the goal is to reinforce EEG activity in the faster beta frequency range (16 to 20 Hz) in the midline cortical regions, and it is targeted at reducing symptoms of impulsivity and hyperactivity. In contrast, theta suppression aims to reduce EEG activity in the slower theta frequency range (4 to 8 Hz) and is used primarily to treat symptoms of inattention.

Controlled studies that compared EEG biofeedback to a stimulant medication with a wait list report consistent beneficial clinical effects and EEG normalization with SMR and theta suppression EEG biofeedback protocols.18,19 However, causal relationships between improvements in attention and increased or decreased alpha activity (12 to 18 Hz) have not been clearly established. The significance of most findings on EEG biofeedback is limited by study design flaws that include small study sizes, heterogeneous populations, absence of a control (ie, sham biofeedback) group, inconsistent outcome measures, self-selection bias (the majority of enrolled subjects were highly motivated to receive treatment), and limited or no long-term follow-up.

Natural products used to treat ADHD. The finding that children with ADHD have lower plasma concentrations of certain essential fatty acids (EFAs) than those in a healthy population has led to the hypothesis that fatty acid deficiencies during critical developmental phases increase the risk of acquiring ADHD.20,21 Few controlled studies have examined the effect of EFAs in children with ADHD, and findings are inconsistent.

One study on EFAs as an adjunctive therapy to stimulant medications found no differential benefit of EFAs compared with stimulants plus a placebo.22 Another adjunctive study found only modest improvements over placebo in disruptive behavior and attention.23

In a placebo-controlled trial on EFAs as a stand-alone treatment of ADHD, parents of children in the treatment group reported more improvement than did parents of children receiving a palm oil placebo.24 This study has been criticized because a high dropout rate biases findings in a positive direction.14 The use of olive oil(Drug information on olive oil) as a placebo may mask the beneficial clinical effects of EFAs because an active constituent of olive oil is converted into oleamide, which is known to affect brain function.25 It has also been suggested that the relatively short durations and low doses of EFAs used in these studies may not be adequate to result in changes in neuronal membrane structure required for clinical improvement.22

The issue of dosing has been addressed by a small open-label study (N = 9) in which children with ADHD were given supplemental high-dose eicosapentaenoic acid/docosahexaenoic acid (EPA/DHA) concentrates (16.2 g/d) while they continued to take stimulant medications. Most children were rated by a blinded psychiatrist as having significant improvements in both inattention and hyperactivity that correlated with reductions in the arachidonic acid to EPA ratio at the end of an 8-week treatment.26 Large prospective trials in different age-groups are needed to replicate these findings before omega-3s can be generally recommended for ADHD.

Herbal preparations

In a 4-week study, 36 children with ADHD were randomized to an herbal preparation containing Ginkgo biloba(Drug information on ginkgo biloba) and Panax quinquefolius (American ginseng) or to a combination of the herbal preparation and stimulant medication.27 Beneficial effects in attention and impulsivity were observed in children taking the herbal preparation alone; however, the absence of a comparison group (ie, taking a stimulant only) and small study size limit the significance of the findings.

Findings of several open studies suggest that a standardized extract of Pinus pinaster (French maritime pine) bark is an effective treatment of ADHD, although to date, only 1 double-blind placebo-controlled trial has been published.28 Children and adolescents randomized to a standardized extract of French maritime pine bark (Pycnogenol, 1 mg/kg/d for 1 month) experienced significant improvements in hyperactivity, inattention, and visual-motor coordination over those receiving placebo; however, symptoms returned to pretreatment baseline levels after a 1-month washout.28 One case of mild gastric discomfort was reported, and there were no serious adverse effects. Well-designed controlled studies are needed to replicate these preliminary findings.

Bacopa monnieri (Brahmi) is an Ayurvedic medicinal herbal preparation that is widely used as a tonic and memory enhancer. In a small, 12-week double-blind randomized clinical trial (RCT), 36 children who had ADHD and who were randomized to bacopa 50 mg twice a day showed significant improvement over those receiving placebo in tests of sentence repetition, logical memory, and pair-associative learning.29 Large placebo-controlled trials are needed to confirm the safety and efficacy of bacopa as a treatment of ADHD.

Supplementation with trace elements

Zinc. Children who have ADHD frequently have abnormally low plasma zinc levels, which may interfere with optimal information processing and correlate with the severity of inattentive symptoms.30,31 Zinc supplementation is a widely used alternative treatment of ADHD; nevertheless, few studies have been done and findings are inconsistent. In a large 12-week double-blind placebo-controlled trial (N = 400), children and adolescents who were randomized to a high dose of zinc (150 mg/d) experienced significant improvement in hyperactivity and impulsivity but not inattention over those receiving placebo.32 A high dropout rate limits the significance of these findings.

In another study, the addition of zinc to methylphenidate therapy resulted in greater improvement than methylphenidate alone.33 Large prospective studies are needed to replicate these preliminary findings and to confirm optimum dosing of zinc sulfate(Drug information on zinc sulfate).34

Iron. The incidence of iron deficiency as measured by serum ferritin levels may be higher in children with ADHD than in a matched population of children without ADHD.35 Abnormally low serum ferritin levels may be associated with relatively greater hyperactivity in non-anemic children with ADHD but not with differences in cognitive performance tasks.36 In an open trial, non–iron-deficient children given oral iron for 1 month were perceived as less hyperactive and distractible by teachers—but not by parents.37

In a small, 12-week placebo-controlled trial, non-anemic children with ADHD who had abnormally low serum ferritin levels were randomized to oral iron (ferrous sulfate, 80 mg/d). Progressive improvements in the severity of ADHD symptoms were observed relative to placebo throughout the study: the effect was comparable to clinical improvements obtained with stimulants.35 Large controlled studies are needed to confirm putative beneficial effects of iron supplementation in ADHD and to determine optimal dosing.

Acetyl-L-carnitine is required for energy metabolism and synthesis of fatty acids. Findings from a small study suggest that acetyl-L-carnitine significantly reduces the severity of ADHD symptoms. However, study design flaws, including failure to report pretreatment and posttreatment symptoms, limit the significance of the findings.38 In a multisite, 16-week pilot study, 112 children with ADHD, aged 5 to 12 years, were randomized to placebo or to acetyl-L-carnitine (500 to 1500 mg bid).39 The Conners parent and teacher rating scales administered at baseline, and at 8, 12, and 16 weeks showed the superiority of acetyl-L-carnitine over placebo in inattentive-type children; however, there was no improvement over placebo in combined-type children. Significant adverse effects were not reported. Future studies are warranted to examine specific therapeutic effects of acetyl-L-carnitine in the inattentive type of ADHD. Findings of a small randomized placebo-controlled study suggest that acetyl-L-carnitine given in doses of 50 mg/kg/d improves symptoms of hyperactivity in young boys with fragile X syndrome and ADHD.40

Homeopathic remedies

Homeopathic remedies are widely used in the United States and other countries to treat or self-treat ADHD. A recent systematic review of RCTs on homeopathic treatments in ADHD concluded that there is no evidence of beneficial effects of homeopathy on symptom severity, core symptoms, or the course of ADHD.41

Frei and colleagues42 have pointed out that conventional RCT study designs may interfere with the goal of demonstrating clinically relevant treatment effects of specific homeopathic remedies for ADHD. They suggest that long-term studies are needed that incorporate an initial open-label phase to identify the optimal treatment for each patient who can then be randomized to his or her optimum remedy or to a randomly selected homeopathic preparation in a subsequent placebo-controlled phase.

Yoga and massage

In a small pilot study, children with ADHD randomized to yoga experienced more significant reductions in symptoms over time than children assigned to a conventional exercise group. Children who continued to take stimulants while practicing yoga experienced the greatest improvements.43 Two small controlled studies suggest that yoga and regular massage therapy may reduce the severity of ADHD symptoms.44,45 Large prospective studies are needed to confirm beneficial effects and test for possible group expectation effects of yoga and massage in ADHD.

Green play environments

A recently proposed theory conceptualizes ADHD as the result of attention fatigue caused by limited contact with green spaces during early childhood development. Findings of a large observational study suggest that children with ADHD who spend more time playing outdoors in natural environments may experience fewer and less severe symptoms of ADHD.46 These findings have been criticized because of design flaws, including a highly heterogeneous population that included children with severe symptoms or comorbid oppositional-defiant disorder, absence of independent raters, absence of a comparison group, and reliance on the impressions of parents using nonstandardized rating scales.47

Summary of key findings

To be most effective, the integrative management of ADHD should be individualized, taking into account the specific causes of the syndrome in each patient, including genetic factors, perinatal insults or toxic exposure, food sensitivities, and social factors. Stimulant and nonstimulant medications are often beneficial and are well tolerated for a significant percentage of children, adolescents, and adults with ADHD. When stimulants are ineffective, poorly tolerated, or refused by the patient (or the patient’s parents), validated EEG biofeedback protocols—including SMR training for primarily hyperactive-type ADHD and theta suppression for primarily inattentive-type ADHD—are reasonable alternatives.

The Table summarizes significant research findings for the nonconventional and integrative therapies for ADHD discussed in this article. Dietary restrictions on food colorings and additives or on foods that may be causing allergic reactions may significantly reduce symptoms of hyperactivity in some cases. Zinc supplementation may be helpful in cases when hyperactivity and impulsive behavior do not respond to stimulants alone. Emerging findings suggest that supplementation with iron and acetyl-L-carnitine may reduce symptoms of distractibility and inattention in some cases of ADHD. Large prospective placebo-controlled studies are needed before zinc, iron, or acetyl-L-carnitine can be generally recommended for the treatment of ADHD. High doses of omega-3 EFAs (up to 16 g/d) may have beneficial effects on symptoms of both inattention and hyperactivity. More studies are needed to determine the optimal form and dosing of omega-3s in children and adults in whom ADHD is diagnosed. Extracts of Ginkgo biloba, Panax quinquefolius, Pinus pinaster, and Bacopa monnieri may be beneficial; however, conclusive findings from large prospective controlled trials are needed before any of these herbal preparations can be recommended as adjunctive or first-line treatments.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.

  • Oldest First
  • Newest First

by Tim Earnest | July 21, 2010 11:02 PM EDT

ADHD and Trace Elements
ADHD has been associated with a number of abnormalities in trace elements.  Rather than evaluating each element alone, perhaps evaluating them together will shed light on their full influence.  Trace elements related to ADHD include elevated lead exposure (1), deficiency in iron (2), and deficiency in zinc (3).  Of interest is that in an animal model, dietary zinc has a protective effect upon exposure to organophosphates, and organophosphate exposure leads to low levels of zinc (4).  This may explain recent implications in elevated rates of ADHD in those children exposed to organophosphates (5).  In addition, given the divalent metal transporter could be involved in one's absorption of all of these trace metals from the GI tract, this transporter and its functioning or lack thereof may have a significant role in explaining the long-pondered association between GI functioning and ADHD.

1.  Nigg, Joel, et al., Confirmation and extension of association of blood lead with ADHD and ADHD symptom domains at population-typical exposure levels,  Journal of Child Psychology and Psychiatry, and Applied Disciplines, 2010 Jan;  51(1): 58-65.
2.  Konofal, Eric, et al., Iron deficiency in children with attention-deficit / hyperactivity disorder, Archives of Pediatrics and Adolescent Medicine, 2004 Dec; 158(12): 1113-5.
3.  Bilici, Mustafa, et al., Double -blind, placebo controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder, Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2004 June; 28(1): 181-90.
4.  Goel, Ajay and Dhawan, Devinder, Zinc Supplementation Prevents Liver Injury in Chlorpyrifos-Treated Rats, Biological Trace Element Research, 2001 June; 82(1-3): 185-200.
5.  Bouchard, Maryse, et al., Attention-Deficit/Hyperactivity Disorder and Urinary Metabolites of Organophosphate Pesticides, Pediatrics, 2010 June; 125(6): e1270-e1277.

Tim Earnest, MD
Pediatric Psychiatrist
932 13th St SW
Puyallup, WA  98371
(253) 232-7570
No conflict of interest to declare

by kirk little | January 27, 2011 11:24 AM EST

Refreshing, Dr. Lake, that you are exploring the evidence for ADHD treatments beyond medication. 

The research on EEG Biofeedback has really taken off lately, so you may be interested in some of the more recent studies coming out in the past year or two, with large N, randomized subjects, blinded ratings, and sham or alternative tx controls, such as using computerized attention training. 

There's even been a meta-analysis of these more recent studies published by Arns et al, and a paper addressing the evidence for Neurofeedback as an efficacious and specific treatment for ADHD. 

ISNR.org would be a good place to start. 

Best wishes,
Kirk D. Little, Psy.D.

Related content

Alternative Medicine Therapies for ADHD

Integrative Management of ADHD: What the Evidence Suggests






 
TOPIC INDEX

Addiction Medicine
Alzheimer Disease
Anxiety Disorders
ADHD
Bipolar Disorder
Child & Adolescent Psychiatry
Dementia
Depression
DSM-5
Geriatric Psychiatry

 

Health Care Reform
Major Depressive
Disorder
OCD
Personality Disorders
Schizoaffective Disorder
Schizophrenia
Sleep Disorders
Somatoform Disorders
All Topics

 


 
RELATED TOPICS

Attention deficit and disruptive behavior disorders
Hyperkinetic syndrome
Minimal brain dysfunction

 
FROM PHYSICIANS PRACTICE
Five Steps to Improving Patient Access
Judy Capko,  May 21, 2013
Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.
Growing HIPAA Threat – Ignore Windows XP at Your Own Peril
Marion K. Jenkins,  May 21, 2013
Chances are good that you have some major ticking software time bombs lurking in your medical practice's computer environment, namely Windows XP and Server 2003.
Finding Physician Work-Life Balance in the Small Moments
Jennifer Frank, MD,  May 21, 2013
At my practice and at home, things are always busy. There's laundry or homework, or a patient with needs.
Three Areas to Reduce Costs at Your Medical Practice
Greg Mertz,  May 19, 2013
By taking a hard look at reducing costs for staffing, overhead, and technology at your medical practice, you may see increased physician compensation.
Dos and Don’ts for Starting a Physician Blog
Michael Woo-Ming, MD,  May 18, 2013
Starting a physician blog can provide your medical practice with marketing benefits, but it's important to do it right.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Developmental Psychopathology Comes of Age
  • The Moral Struggles of Practicing Psychiatrists
  • Grief and Depression: The Sages Knew the Difference
  • Update on Mental Health Benefits and Substance Use Disorder Services Under the Affordable Care Act
  • Synthetic Cathinones: Signs, Symptoms, and Treatment
  • Grief and Depression: The Sages Knew the Difference
  • Successful Aging: Strategies to Help Maintain and Nurture a Healthy Brain
  • Synthetic Cathinones: Signs, Symptoms, and Treatment
  • Developmental Psychopathology Comes of Age
  • Psychiatry and the Myth of “Medicalization”
  • The Role of Biological Tests in Psychiatric Diagnosis
  • You Are—And Your Mood Is—What You Eat
  • Experts Discuss Changes, Updates in DSM-5
  • The Paradox of Choice: When More Medications Mean Less Treatment
  • Will Your Clinical Records Support You in Court?
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • Grief and Depression: The Sages Knew the Difference
  • Psychiatry and the Myth of “Medicalization”
  • Is it Time for a Treatment Manual to Complement DSM-5?
  • NIMH vs DSM 5: No One Wins, Patients Lose
  • DSM-5 Won’t Solve the Overdiagnosis Problem—But Clinicians Can
  • DSM-5 Won’t Solve the Overdiagnosis Problem—But Clinicians Can
  • The Paradox of Choice: When More Medications Mean Less Treatment
  • Experts Discuss Changes, Updates in DSM-5
  • New Insight Into the Neurobiology of Depression
  • Tie One On for Patients
Click here to subscribe to our newsletter
 
CAREER CENTER

  •   Featured Jobs  
  •    Resources   
  • Psychiatry and Nurse Practitioner Opportunities
  • Associate Medical Director - Psychiatrist Delray Beach, Florida
  • Retiring Child Psychiatrist Seeks Replacement August 2010 or Before
  • Chairperson, Dept of Psychiatry Needed
  • FT Staff Psychiatrist - Excellent Benefits
  • BC Adult and Child Psychiatrits - PT and FT Positions Available
  • Managing Risks When Practicing in Three-Party Care Settings
  • 12 Tips for Making Your Practice Greener
  • Keys to Avoiding Malpractice: Standard of Care in Psychiatric Practice
  • Take This Job and Shove It
  • Merging Administrative and Academic Careers in Psychiatry


 
SearchMedica Search Result

Find peer-reviewed literature and websites for practicing medical professionals

CME on Adhd
Evidence on Adhd
Guidelines on Adhd
Patient Education on Adhd
Clinical Trials on Adhd
Practical Articles on Adhd
Research and Reviews on Adhd
All "Adhd" results

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy